Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (231-240 of 825) with videos related to

Pageof 83
Sort By:
Clinical Chemistry|May 19, 2011
Circulating cancer cells and their clinical applicationsEleftherios P Diamandis, Klaus Pantel, Howard I Scher, et al.
Headache|June 6, 2009
Obesity and migraine: the effect of age, gender and adipose tissue distributionB Lee Peterlin, Andrea L Rosso, Alan M Rapoport, et al.
Transplantation|July 1, 1976
Functional characterization of a naturally occurring antibody cytotoxic for a subpopulation of splenic T cellsT Ochiai, A Ahmed, I Scher, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1984
Changes in the expression of B cell surface markers on complement receptor-positive and complement receptor-negative B cells induced by phorbol myristate acetateT Lindsten, C B Thompson, F D Finkelman, et al.
Investigational New Drugs|January 1, 1986
Phase II trial of 10 deaza-aminopterin in patients with bladder cancerT Ahmed, A Yagoda, H I Scher, et al.
Plos One|October 14, 2015
Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression ModelHoward I Scher, Kirk Solo, Jason Valant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancerFrancis M Sirotnak, Yohung She, Fei Lee, et al.
Anticancer Research|November 1, 1984
Phase II trial of 10-deazaaminopterin for advanced hypernephromaH I Scher, A Yagoda, T Ahmed, et al.
Oncology (Williston Park, N.Y.)|October 23, 1997
Combined-modality therapy for bladder cancerJ A McCaffrey, D F Bajorin, H I Scher, et al.
Folia Biologica|January 1, 1976
Studies on non-H-2 linked lymphocyte activating determinants. III. Influence of the X-chromosome and correlation of the density of surface Ig with the appearance of the MLs product [proceedings]A Ahmed, I Scher, A Smith, et al.
Pageof 83

Showing results (231-240 of 825) with videos related to

Sort By:
Pageof 83
Clinical Chemistry|May 19, 2011
Circulating cancer cells and their clinical applicationsEleftherios P Diamandis, Klaus Pantel, Howard I Scher, et al.
Headache|June 6, 2009
Obesity and migraine: the effect of age, gender and adipose tissue distributionB Lee Peterlin, Andrea L Rosso, Alan M Rapoport, et al.
Transplantation|July 1, 1976
Functional characterization of a naturally occurring antibody cytotoxic for a subpopulation of splenic T cellsT Ochiai, A Ahmed, I Scher, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1984
Changes in the expression of B cell surface markers on complement receptor-positive and complement receptor-negative B cells induced by phorbol myristate acetateT Lindsten, C B Thompson, F D Finkelman, et al.
Investigational New Drugs|January 1, 1986
Phase II trial of 10 deaza-aminopterin in patients with bladder cancerT Ahmed, A Yagoda, H I Scher, et al.
Plos One|October 14, 2015
Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression ModelHoward I Scher, Kirk Solo, Jason Valant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancerFrancis M Sirotnak, Yohung She, Fei Lee, et al.
Anticancer Research|November 1, 1984
Phase II trial of 10-deazaaminopterin for advanced hypernephromaH I Scher, A Yagoda, T Ahmed, et al.
Oncology (Williston Park, N.Y.)|October 23, 1997
Combined-modality therapy for bladder cancerJ A McCaffrey, D F Bajorin, H I Scher, et al.
Folia Biologica|January 1, 1976
Studies on non-H-2 linked lymphocyte activating determinants. III. Influence of the X-chromosome and correlation of the density of surface Ig with the appearance of the MLs product [proceedings]A Ahmed, I Scher, A Smith, et al.
Pageof 83